Kolbjørn Zahlsen

Iodinin (1,6-Dihydroxyphenazine 5,10-Dioxide) from Streptosporangium sp. Induces Apoptosis Selectively in Myeloid Leukemia Cell Lines and Patient Cells

Despite recent improvement in therapy, acute myeloid leukemia (AML) is still associated with high lethality. In the presented study, we analyzed the bioactive compound iodinin (1,6-dihydroxyphenazine 5,10-dioxide) from a marine actinomycetes bacterium for the ability to induce cell death in a range of cell types. Iodinin showed selective toxicity to AML and acute promyelocytic (APL) leukemia cells, with EC50 values for cell death up to 40 times lower for leukemia cells when compared with normal cells. Iodinin also successfully induced cell death in patient-derived leukemia cells or cell lines with features associated with poor prognostic such as FLT3 internal tandem duplications or mutated/deficient p53. The cell death had typical apoptotic morphology, and activation of apoptotic signaling proteins like caspase-3. Molecular modeling suggested that iodinin could intercalate between bases in the DNA in a way similar to the anti-cancer drug daunorubicin (DNR), causing DNA-strand breaks. Iodinin induced apoptosis in several therapy-resistant AML-patient blasts, but to a low degree in peripheral blood leukocytes, and in contrast to DNR, not in rat cardiomyoblasts. The low activity towards normal cell types that are usually affected by anti-leukemia therapy suggests that iodinin and related compounds represent promising structures in the development of anti-cancer therapy.

Anti-microbial and cytotoxic 1,6-dihydroxyphenazine-5,10-dioxide (iodinin) produced by Streptosporangium sp. DSM 45942 isolated from the fjord sediment

Phenazine natural products/compounds possess a range of biological activities, including anti-microbial and cytotoxic, making them valuable starting materials for drug development in several therapeutic areas. These compounds are biosynthesized almost exclusively by eubacteria of both terrestrial and marine origins from erythrose 4-phosphate and phosphoenol pyruvate via the shikimate pathway. In this paper, we report isolation of actinomycete bacteria from marine sediment collected in the Trondheimfjord, Norway. Screening of the isolates for biological activity produced several “hits”, one of which was followed up by identification and purification of the active compound from the actinomycete bacterium Streptosporangium sp. The purified compound, identified as 1,6-dihydroxyphenazine-5,10-dioxide (iodinin), was subjected to extended tests for biological activity against bacteria, fungi and mammalian cells. In these tests, the iodinin demonstrated high anti-microbial and cytotoxic activity, and was particularly potent against leukaemia cell lines. This is the first report on the isolation of iodinin from a marine-derived Streptosporangium.

Rapid metabolic profiling of developing Pseudomonas aeruginosa biofilms by high-resolution mass spectrometry fingerprinting

Biofilms are single- or multi-species communities of bacteria that are enclosed in an extracellular matrix. These cells generally exhibit phenotypes that are significantly different from those of planktonic cells, yet detailed elucidation of the causality and the exact nature of this metabolic shift remains challenging. Considering the strong correlation of biofilms with pathogenicity and disease in the clinic, as well as the veritable economic impact of biofilms in other areas, a methodology for in-vivo monitoring of biofilm development is necessary. Here, we present high-resolution mass spectrometry fingerprinting as a rapid, sensitive, and generic technique for online, non-invasive monitoring of developing biofilms. The opportunistic pathogen Pseudomonas aeruginosa is used as a model system, and it is demonstrated that strain- and time-dependent changes in biofilm extracellular metabolites are easily detected.

Two-dimensional LC-MS fractioning and cross-matching of mass spectrometric data for rational identification of bioactive compounds in crude extracts.

Bioprospecting aims at the identification of biological compounds with novel properties. Identification of such compounds in crude complex biological extracts is a comprehensive challenge. As a large number of extracts must be screened for successful identification of one potential promising lead, rational screening strategies must be developed. Here we report on a novel two stage rational LC-MS strategy of extracts already pre-screened and proven to contain bioactive compound(s). All extracts are initially fractionated using one and the same LC condition with parallel mass spectrometric detection. Fractions containing bioactive compound(s) are then subjected to a second fractional stage using two different chromatographic conditions. Mass detection is also included at this stage, and a cross-matching algorithm for comparison of processed mass chromatograms from the two dimensions was developed. The algorithm reports only masses present in bioactive fractions in both dimensions and enable therefore an efficient identification of potential masses that causes the bioactivity. This mass list can be used to search in natural compound database(s) for a rapid evaluation if the mass belongs to an already identified compound or if it is a potentially new one. This strategy enables thorough screening of several hundred crude extracts in one week on one single instrument.